POLARIS INSIGHTS

Bio-Rad reaffirms 2026 currency-neutral revenue growth at (-3%) to 0. 5% while targeting non-GAAP operating margin in upper half of 10% to 12% range

This story focuses on Bio-Rad reaffirms 2026 currency-neutral revenue growth at (-3%) to 0. 5% while targeting….

More from the Markets desk